Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric K Rowinsky

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
Clinical Colorectal Cancer|August 3, 2004
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancerAlain C Mita, Monica M Mita, Eric K Rowinsky
Cancer|February 4, 2010
Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10Hagop Youssoufian, Eric K Rowinsky, James Tonra, et al.
Breast Cancer Research : BCR|June 10, 2003
The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Seminars in Oncology|November 13, 2003
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinomaJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Cancer|February 4, 2010
Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)Jonathan D Schwartz, Eric K Rowinsky, Hagop Youssoufian, et al.
Investigational New Drugs|October 28, 2003
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellumSeamus O'Reilly, Elizabeth O'Hearn, Robert F Struck, et al.
Cancer|February 4, 2010
Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alphaGaurav D Shah, Nick Loizos, Hagop Youssoufian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptorEric K Rowinsky, Hagop Youssoufian, James R Tonra, et al.
Investigational New Drugs|January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectumMelanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)George W Sledge, Donna Neuberg, Patricia Bernardo, et al.
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
Clinical Colorectal Cancer|August 3, 2004
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancerAlain C Mita, Monica M Mita, Eric K Rowinsky
Cancer|February 4, 2010
Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10Hagop Youssoufian, Eric K Rowinsky, James Tonra, et al.
Breast Cancer Research : BCR|June 10, 2003
The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Seminars in Oncology|November 13, 2003
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinomaJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Cancer|February 4, 2010
Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)Jonathan D Schwartz, Eric K Rowinsky, Hagop Youssoufian, et al.
Investigational New Drugs|October 28, 2003
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellumSeamus O'Reilly, Elizabeth O'Hearn, Robert F Struck, et al.
Cancer|February 4, 2010
Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alphaGaurav D Shah, Nick Loizos, Hagop Youssoufian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptorEric K Rowinsky, Hagop Youssoufian, James R Tonra, et al.
Investigational New Drugs|January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectumMelanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)George W Sledge, Donna Neuberg, Patricia Bernardo, et al.
Pageof 12